Cabaletta Bio, Inc.
NASDAQ:CABABiotechnology
+$0.04 today
- Market cap
- $227.58M
- Beta
- 3.23
- P/E (TTM)
- -1.8
- EPS (TTM)
- -$1.57
Volume 4.13M
Average 3.33M
CABA Other Income / Expenses
Net non-operating gains and losses, such as investment results, currency effects, and one-off items.
Cabaletta Bio, Inc.NASDAQ: CABA
Other Income / Expenses · Q1 FY2026 · quarter ended Mar 2026
Other income / expenses declines year over year
Q1 FY2026 other income / expenses of $781K fell 34.5% year over year, ahead of the -46.9% change in trailing-twelve-month other income / expenses. Sequentially, it rose 12.9% from the prior quarter. Over 3 fiscal years it compounded at +55.6% a year.
Context
- Other income / expenses increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of -34.5% holds above the trailing-twelve-month pace of -46.9%.
Sources:Income StatementText generated from reported figures; not investment advice.
Other Income / Expenses history
USD · from the income statement
- Latest · FY2025
- 4.39M USD
- Year-over-year change
- -52.7%
- 4-year CAGR
- +267.7%
| Period | Period end | Other Income / Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 4.39M | -52.7% |
| FY2024 | 2024-12-31 | 9.28M | +32.8% |
| FY2023 | 2023-12-31 | 6.99M | +500.1% |
| FY2022 | 2022-12-31 | 1.16M | +4750.0% |
| FY2021 | 2021-12-31 | 24K | — |
Other Income / Expenses vs competitors
How CABA compares with its peers on the latest reported figures
- Peers report in different currencies, so other income / expenses is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -46.9% is the 7th highest of 11, against a peer median of -36.4%.
- Over three fiscal years its annual growth of +55.6% compares with a peer median of +66.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| FY2025 | A$64.99M AUD | +43.2% | +241.9% | 1288.5% | |
| LTM Mar 2026 | $16.46M USD | -3.2% | — | — | |
| LTM Mar 2026 | $16.3M USD | -51.1% | -2.8% | 808.4% | |
| LTM Mar 2026 | $14.02M USD | -40.6% | +13.7% | — | |
LXEOLexeo Therapeutics, Inc. Common Stock | LTM Mar 2026 | $10.28M USD | +47.5% | +96.1% | — |
| LTM Mar 2026 | $7.39M USD | -51.5% | +158.9% | — | |
| LTM Mar 2026 | $6.16M USD | -32.3% | — | 15.9% | |
| LTM Mar 2026 | $5.34M USD | +140.8% | +66.0% | — | |
| LTM Mar 2026 | $3.97M USD | -46.9% | +55.6% | — | |
| LTM Mar 2026 | €840.44K EUR | -70.3% | +16.3% | 6.3% | |
| LTM Mar 2026 | -$54.54M USD | -309.6% | — | 175948.4% | |
| Peer median (excluding CABA) | — | -36.4% | +66.0% | 808.4% | |
Competitors are the stored peer set for CABA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 32.49M | 39.3M | 55.42M | 97.2M | 142.67M |
| Selling, General & Admin | 13.82M | 14.84M | 19.24M | 27.94M | 29.57M |
| Operating Expenses | 46.31M | 54.14M | 74.66M | 125.14M | 172.24M |
| Depreciation & Amortization | 733K | 1.18M | 1.43M | 1.71M | 1.65M |
| EBITDA | (45.56M) | (51.8M) | (66.25M) | (113.41M) | (164.21M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (46.31M) | (54.14M) | (74.66M) | (125.14M) | (172.24M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 24K | 1.16M | 6.99M | 10.03M | 6.03M |
| Interest Expense | 0 | 0 | 0 | 748K | 2M |
| Other Income / Expenses | 24K | 1.16M | 6.99M | 9.28M | 4.39M |
| Income Before Tax | (46.29M) | (52.98M) | (67.68M) | (115.86M) | (167.86M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (46.29M) | (52.98M) | (67.68M) | (115.86M) | (167.86M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (1.80) | (1.81) | (1.65) | (2.34) | (1.64) |
| EPS (Diluted) | (1.80) | (1.81) | (1.65) | (2.34) | (1.64) |
| Weighted Avg Shares | 25.74M | 29.34M | 40.95M | 49.52M | 102.26M |
| Weighted Avg Shares (Diluted) | 25.74M | 29.34M | 40.95M | 49.47M | 102.26M |
Cabaletta Bio, Inc.
NASDAQ:CABA
Intrinsic Alpha fair value
Locked
Current Price
$1.06
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.